Member Info for Sangijuelas1

But they could be the same person running a con to pump the stock. Anonymous posters on here and Twitter are accountable to no one.

Some pump and dump ops are quite sophisticated and all cons are eminently plausible especially if they are telling people what they want to hear.

Robbo, when your friend told you to take your profit based on concrete inside info, why did you not listen to them?

Why are you inclined to listen to them now?

Is our song for the day!

Plenty of marks here though so fertile ground

All sounds so plausible. Thankfully I make my decisions based on verifiable facts rather than rumours spread by anons on BBs

Mummy mummy I lost all my money listening to a bot on Twitter run by a pump and dump crew

Robbo Ophidian mmmm..

See you in 3 years then

Yeah there is some discussion of gene changes on the SITC presentation and the slides on the 4D website but I don't know whether they will have more to report on that.

With the biomarkers bit on the combo trial I remember them previously saying they were doing more analysis, which will be released at a later date so presumably they will be talking about that.

I will be here long after many of you have gone because you hit £3 a share

That has already been shown as proof of concept and that trial is due to be expanded soon

Ok it's just someone else said it here and it's a theme on the ADVFN board.

If the ESMO stuff was really exciting Shubham Pant would be presenting it from MD Anderson but looks like his deputy

Anyone thinking the Oncology Update is on the 16 September is wrong. It could come anytime. Late summer, early autumn.

Amazing that someone has to go to those lengths to keep a lid on it.

I counted 26 autosells at 1.24pm. They are definitely having to work overtime

If there were enough buyers to overcome the shorters autosells this would rocket.

The main data was already presented at SITC last year. They will be presenting a further analysis of the previously released data with more info on the identification of biomarkers from the combo trial and genetics analysis from the monotherapy trial.

So the data will be relevant as it will be added to the whole regulatory package but this is a sideshow from the actual Oncology Update, which will involve interim data from the Phase 1B trial extension.

One of the things people don't get is that immunotherapy drugs like Keytruda and Bavencio are multi billion £ markets but they only work for 25-30% of patients.

If 4D main oncology candidate MRx0518 can increase the efficacy of those treatments by even as little as a small percentage amount that would be massive.

Last placing at 110p including director buys and Merck taking a further chunk. Good enough credit risk to secure a loan from Oxford Finance so funded until the end of next year.

Updates due on 0518 /Keytruda combo and the asthma drug.

Partnerships in place with Merck and Pfizer.
Multiple recent microbiome articles for both academics and investors referencing 4D.

Decision due later in the year on how to take Blautix through to pivotal trial.

In addition to 0518 for oncology , the Micro RX platform has turned up a second generation of LBPs for cancer.

Trials due to start for 0518 with Bavencio and the drugs for neurodegenerative in Parkinsons.

Issues with Seres and others consortia approach (failed trials etc) makes me more confident in the single strain approach that is able to clearly demonstrate functionality and causation rather than correlation. The regulators will like that.

Company is targeting not just new drugs but a new area of medicine. There is still not a single LBP approved. Various candidates have completed P3 and when an approval comes interest in the sector will increase greatly.

Safety profile of the LBPs is key. If the drug works for severe asthma, patients will be able to stop taking corticosteroids, which are extremely debilitating with multiple side effects.

It would indeed. Stimulating or dampening immune response is key for many vaccines efficacy.